Cancer mortality in trials using vitamin D3 (cholecalciferol) ( · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower cancer mortality in trials using vitamin D₃(cholecalciferol) compared with placebo or no intervention (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in mortality (all infants): 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in mortality (all infants): 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower all‐cause mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Mortality rate ( · children with acute pneumonia
Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adults with HIV infection
It is very uncertain whether vitamin D changes mortality compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with HIV infection
1 finding from 1 review
All‐cause mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · children under 5 years of age
1 finding from 1 review
Liver‐related mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes liver‐related mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Cause‐specific mortality · children under 5 years of age
1 finding from 1 review